| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Bz-Arg-Oet.HCl targets trypsin-like enzymes as a selective inhibitor. It is a competitive inhibitor of trypsin and has been studied for its effects on thrombin and other serine proteases. Its primary application is as a biochemical reagent for studying protease activity and inhibition. The benzoyl group provides N-terminal protection, while the ethyl ester provides C-terminal protection.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro, Bz-Arg-Oet.HCl acts as a selective inhibitor of trypsin-like enzymes. It is a competitive inhibitor of trypsin and has been shown to inhibit thrombin activity. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. Bz-Arg-Oet.HCl is used in biochemical assays to study protease inhibition and substrate specificity. |
| ln Vivo |
In vivo, Bz-Arg-Oet.HCl has been studied for its effects on coagulation and blood pressure. It has been found to be a competitive inhibitor of trypsin and has been shown to inhibit thrombin activity. It is used in experimental models to investigate protease inhibition and its therapeutic potential in conditions involving aberrant proteolysis.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for Bz-Arg-Oet.HCl involve measuring its inhibition of trypsin or thrombin activity. Purified enzyme is incubated with the compound at various concentrations in appropriate buffer with a chromogenic or fluorogenic substrate. Enzyme activity is measured spectrophotometrically or fluorometrically. IC50 or Ki values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based protocols for Bz-Arg-Oet.HCl are not well established as it is primarily a biochemical reagent. In cell culture, it may be used to study the role of proteases in cellular processes. Cells are treated with concentrations ranging from 0.1-100 µM for 1-24 hours, and protease activity or downstream signaling is assessed.
|
| Animal Protocol |
In vivo animal study protocols for Bz-Arg-Oet.HCl involve administration via intravenous or intraperitoneal injection in animal models. Dosing typically ranges from 1-50 mg/kg depending on the study. Studies may assess effects on coagulation parameters, blood pressure, and protease activity in plasma or tissues. Blood and tissue samples are collected for analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Bz-Arg-Oet.HCl are characteristic of small peptide-like molecules. The compound has a molecular weight of 342.82 g/mol, formula C15H22N4O3·HCl, and CAS number 2645-08-1. Storage is recommended in a cool, dry place. It is a competitive inhibitor of trypsin.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Bz-Arg-Oet.HCl. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions for handling biochemical reagents should be observed. No specific toxicity studies have been reported.
|
| References | |
| Additional Infomation |
Bz-Arg-Oet.HCl (CAS#: 2645-08-1) is also known as Nα-Benzoyl-L-arginine ethyl ester hydrochloride and BAEE. Its molecular formula is C15H22N4O3·HCl. It is a selective inhibitor of trypsin-like enzymes used in biochemical research. It has no approved therapeutic indications.
|
| Molecular Formula |
C15H23CLN4O3
|
|---|---|
| Molecular Weight |
342.8211
|
| Exact Mass |
342.145
|
| CAS # |
2645-08-1
|
| Related CAS # |
971-21-1 (Parent)
|
| PubChem CID |
2723604
|
| Appearance |
White to off-white powder
|
| Density |
1.23g/cm3
|
| Melting Point |
128-130 °C
|
| Index of Refraction |
-17 ° (C=2, H2O)
|
| LogP |
2.995
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
23
|
| Complexity |
388
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].O(C([H])([H])C([H])([H])[H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])N([H])C(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)=O
|
| InChi Key |
HIXDELXKSSLIKB-YDALLXLXSA-N
|
| InChi Code |
InChI=1S/C15H22N4O3.ClH/c1-2-22-14(21)12(9-6-10-18-15(16)17)19-13(20)11-7-4-3-5-8-11;/h3-5,7-8,12H,2,6,9-10H2,1H3,(H,19,20)(H4,16,17,18);1H/t12-;/m0./s1
|
| Chemical Name |
ethyl (2S)-2-benzamido-5-(diaminomethylideneamino)pentanoate;hydrochloride
|
| Synonyms |
Bz-Arg-Oet.HCl; N-Benzoyl-L-arginine ethyl ester hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~729.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9170 mL | 14.5849 mL | 29.1698 mL | |
| 5 mM | 0.5834 mL | 2.9170 mL | 5.8340 mL | |
| 10 mM | 0.2917 mL | 1.4585 mL | 2.9170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
